Clinical Trial

A Study of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, placebo-controlled and multiple dose escalation phase Ib study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM383 in patients with Alzheimer's disease related mild cognitive impairment and mild Alzheimer's disease.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-27.
Status change: Not Yet Recruiting → Recruiting 2025-03-14
Trial Details
NCT Number NCT06619613
Lead Sponsor Keymed Biosciences Co.Ltd
Conditions Alzheimer Disease
Enrollment 48 participants
Start Date 2024-11-08
Primary Completion 2026-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-19